3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Cyclophosphamide
6
Platinum
5
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
lenvatinib
×
1 year
×
Clear all
No trials found.